Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Cocaine; Galantamine

Criteria

Inclusion Criteria:

• Male and females, between the ages 21 and 50

• Fulfill criteria for past cocaine dependence

• No cocaine use for the past 30 days

• No other current dependence or abuse of other drugs or alcohol

• No current medical problems and normal ECG

• Not pregnant,nor breast feeding,

• Using acceptable birth control methods.

Exclusion Criteria:

• Current major psychiatric illness including mood, psychotic or anxiety disorders

• History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances

• Use of other medications including,drugs that slow heart rate

• Known allergy to galantamine